McKean-Dieser Avril Suzette 4
4 · OS Therapies Inc · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
OS Therapies (OSTX) Director Avril McKean-Dieser Receives Stock Award
What Happened
Avril McKean-Dieser, a director of OS Therapies, was granted options to purchase 50,000 shares of the company’s common stock on January 22, 2026. The Form 4 reports the derivative award with an acquisition price of $0.00 (grant of options), and no immediate cash transaction or sale occurred.
Key Details
- Transaction date: 2026-01-22 (Form 4 filed 2026-02-13).
- Transaction type/code: Grant/Award (A) — options to purchase 50,000 shares.
- Reported price/value on Form 4: $0.00 (derivative grant; grant-date fair value not shown).
- Vesting: Options vest in full on the one-year anniversary of the grant (Jan 22, 2027) provided the reporting person remains a director (per footnote).
- Shares owned after transaction: Not specified in the filing.
- Timeliness: Filing was late (filed 22 days after the transaction); Form 4s are normally due within two business days.
Context
This was a stock option grant (a compensation award), not a purchase or sale of shares. Such grants are common for directors and do not represent an immediate market buy or sell. The options will only convert to equity if/when exercised after vesting and subject to any exercise terms. The late filing is a compliance detail investors should note but does not itself indicate trading behavior.
Insider Transaction Report
- Award
Stock options (right to buy)
[F1]2026-01-22+50,000→ 50,000 totalExercise: $1.34Exp: 2036-01-22→ Common Stock (50,000 underlying)
- 5,000
Common Stock
Footnotes (1)
- [F1]On January 22, 2026, the reporting person was granted options to purchase 50,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as a director of the issuer on such date.